---
title: Magnetic pulses detect thinking problems
nct_id: NCT06835595
phase: NA
status: RECRUITING
sponsor: Azienda Sanitaria Universitaria Integrata del Trentino
study_type: INTERVENTIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT06835595"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06835595"
last_fetched: "2026-05-10T14:02:52.116Z"
source: "Parkinson's Pathways (curated)"
---
# Magnetic pulses detect thinking problems

**Goal (in five words):** Magnetic pulses detect thinking problems

**Official Title:** Transcranial Magnetic Stimulation (TMS) Related Measures as Biomarker of Cognitive Impairment in Parkinson's Disease (PD)

**Trial ID:** [NCT06835595](https://clinicaltrials.gov/study/NCT06835595)

## Key Facts

- **Phase:** NA
- **Status:** RECRUITING
- **Study Type:** INTERVENTIONAL
- **Sponsor:** Azienda Sanitaria Universitaria Integrata del Trentino
- **Target Enrollment:** 52 participants
- **Start Date:** 2025-09-10
- **Completion Date:** 2029-01-01
- **Conditions:** Parkinson Disease
- **Interventions:** Transcranial Magnetic Stimulation
- **Intervention Types:** DIAGNOSTIC_TEST

## Summary For Families

The goal is to find noninvasive brain measures that signal cognitive impairment in Parkinson's, so thinking problems can be detected or tracked earlier and more reliably. The approach uses transcranial magnetic stimulation, which delivers brief magnetic pulses to the scalp to probe cortical excitability, connectivity, and plasticity, recording responses that might link to memory and attention changes while participants also get neuropsychological testing. Tests are done while people remain on their usual antiparkinsonian medications, kept stable for at least four weeks, so results reflect typical treatment effects. Adults 18 and older with idiopathic PD who can complete neuropsychological testing and give informed consent are eligible, while people with dementia by MDS criteria, implanted metal or electronic devices, a history of seizures, pregnancy, or certain seizure‑risk medications are excluded.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

* Age \> 18 years
* Ability to undergo an extensive neuropsychological evaluation
* Ability to sign informed consent for the study
* Diagnosed with idiopathic PD according to the latest revision of the MDS criteria
* On stable and optimal antiparkinsonian therapy for at least four weeks

Exclusion Criteria:

* Systemic diseases of significant severity, including cardiovascular and cerebrovascular conditions (e.g., active neoplasms requiring chemotherapy, or end-stage heart failure)
* Presence of any active neurological disease, in addition to PD
* Presence of a cochlear implant, ferromagnetic brain device or near the site of brain stimulation, pacemaker, brain electrodes for DBS, electromechanical devices with IPG, or any other implantable stimulator, including peripheral ones
* History of epilepsy
* History of cerebrovascular, tumor-related, infectious, or metabolic brain conditions predisposing to seizures or causing symptomatic epilepsy
* Pregnancy or breastfeeding
* Alcoholism
* Treatment with anticholinesterase drugs, benzodiazepines, neuroleptics, anticholinergics, or antidepressants in the last month
* Treatment with drugs that lower the seizure threshold (e.g., imipramine, amitriptyline, doxepin, nortriptyline, maprotiline, chlorpromazine, clozapine, foscarnet, ganciclovir, ritonavir, amphetamines, cocaine, MDMA, ecstasy, phencyclidine, ketamine, gamma-hydroxybutyrate, alcohol, theophylline)
* Active cochlear pathology (especially if currently receiving ototoxic drugs, such as aminoglycoside antibiotics)
* Dementia according to the latest revision of the MDS criteria for PDD
```

## Locations (3)

- SC Clinica Neurologica - Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI), Trieste, Friuli Venezia Giulia, Italy _(45.6495, 13.7768)_
  - Paolo Manganotti, MD — (CONTACT) — +39-0403994282 — paolo.manganotti@asugi.sanita.fvg.it
  - Alberto Benussi, MD — (CONTACT) — +39-0403994282 — alberto.benussi@asugi.sanita.fvg.it
- UOC Neuroriabilitazione - Azienda Sanitaria dell'Alto Adige, Sterzing, Trentino-Alto Adige, Italy _(46.8931, 11.4296)_
  - Viviana Versace, MD — (CONTACT) — +39 0472 774 100 — viviana.versace@sabes.it
  - Davide Ferrazzoli, MD — (CONTACT) — +39 0472 774 100 — davide.ferrazzoli@sabes.it
- UOC Neurologia - Azienda Provinciale per i Servizi Sanitari (APSS), Trento, Trentino-Alto Adige, Italy _(46.0679, 11.1211)_
  - Ruggero Bacchin, MD — (CONTACT) — +39-0461903281 — ruggero.bacchin@apss.tn.it
  - Stefania Campostrini, Mac — (CONTACT) — +39-0461903281 — stefania.campostrini@apss.tn.it

## Central Contacts

- Ruggero Bacchin, MD — (CONTACT) — +39-0461903281 — ruggero.bacchin@apss.tn.it
- Stefania Campostrini, MSc — (CONTACT) — +39-0461903281 — stefania.campostrini@apss.tn.it

---

*Canonical: https://parkinsonspathways.com/trial/NCT06835595*  
*HTML version: https://parkinsonspathways.com/trial/NCT06835595*  
*Source data: https://clinicaltrials.gov/study/NCT06835595*